Search
+
    SEARCHED FOR:

    AB CAPITAL STOCK

    Sanjiv Bhasin's top stock picks post yesterday's market bloodbath

    ​I think that is a very healthy correction which has taken place. You have seen the comeback of FMCG. We think insurance, IT, these will be the better place. But this market is a retail-driven market and the retail investor is very sanguine. He is not eitherly optimistic or pessimistic. He will take this with a pinch of salt that we are in a market which is going to be more driven on macro and micro. Oil is at a three-month low.

    F&O Ban List: Aditya Birla Capital, IEX, Bandhan Bank among 11 stocks under trade ban on Friday

    Eleven stocks faced Futures and Options trade ban, while Biocon and Vodafone Idea exited. Sensex and Nifty soared to new peaks in Thursday’s session.

    GIFT Nifty down 60 points; here's the trading setup for today's session

    "We expect this Positive momentum to continue on the back of an improving political environment, continued short covering by FIIs, and strong domestic macros. Sectors like Defence, Banking, and Railways are expected to remain in focus," said Siddhartha Khemka, Head - Retail Research, Motilal Oswal.

    Vodafone Idea approves Rs 2,075 crore preferential allotment to AB Group

    The allotment aggregates to Rs 2,075 crore and will be issued to Oriana Investments Pte Ltd (Aditya Birla Group entity forming part of the promoter group)

    ABS Marine Services shares list at 100% premium over issue price

    ABS Marine Services Share Price: ABS Marine Services' shares made a remarkable debut on the NSE SME platform on Tuesday, opening at Rs 294 per share, which was a 100% premium over the issue price of Rs 147 per share. Prior to its listing, the company's shares were trading in the unlisted market with a premium of Rs 100.

    Sanjiv Bhasin is bullish on these 7 stocks, recommends avoiding Zee

    Sanjiv Bhasin suggests holding RattanIndia for further gains. His top picks include Embassy Office and Wipro, with potential gains to Rs 450 and Rs 700, respectively. Zydus and Lupin stand out in pharma, while Zee remains an avoid due to management issues.

    The Economic Times
    BACK TO TOP